Open AccessAlternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression
Author(s) -
Éric Lévesque,
Adrien Labriet,
Hélène Hovington,
Éric P. Allain,
Luciana Melo-Garcia,
Michèle Rouleau,
Hervé Brisson,
Véronique Turcotte,
Patrick Caron,
Lyne Villeneuve,
Mickaël Leclercq,
Arnaud Droit,
Étienne Audet-Walsh,
David Simonyan,
Yves Fradet,
Louis Lacombe,
Chantal Guillemette
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0749-2
Subject(s) - prostate cancer , cancer research , biochemical recurrence , biology , prostate , breakpoint cluster region , androgen , metastasis , dihydrotestosterone , medicine , endocrinology , cancer , prostatectomy , gene , hormone , genetics
Perturbation of the major UGT2B17-dependent androgen catabolism pathway has the potential to affect prostate cancer (PCa) progression. The objective was to evaluate UGT2B17 protein expression in primary tumours in relation to hormone levels, disease characteristics and cancer evolution.